WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2023)
Top biotech stocks in 2023 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Forecast Score
Market Cap
Price
Price Target
Upside/Downside
Consensus
Analysts
Fore. Revenue Growth
Fore. Earnings Growth
Forecast ROE
Forecast ROA
ARCT
ARCTURUS THERAPEUTICS HOLDINGS INC
$705.13M$26.51$53.0099.92%Strong Buy448.55%79.94%N/AN/A
HRMY
HARMONY BIOSCIENCES HOLDINGS INC
$2.24B$37.35$59.4359.11%Strong Buy723.27%14.55%N/AN/A
VYGR
VOYAGER THERAPEUTICS INC
$337.81M$7.70$16.00107.93%Strong Buy3-70.03%N/AN/AN/A
OCUP
OCUPHIRE PHARMA INC
$83.19M$3.96$18.50367.17%Strong Buy215.96%-48.65%N/AN/A
UTHR
UNITED THERAPEUTICS CORP
$10.51B$223.93$297.1732.71%Strong Buy68.30%6.42%N/AN/A
KNSA
KINIKSA PHARMACEUTICALS LTD
$1.19B$16.93$32.0089.01%Strong Buy123.76%N/AN/AN/A
BMRN
BIOMARIN PHARMACEUTICAL INC
$16.63B$88.38$113.4128.32%Buy1721.17%99.74%N/AN/A
TECH
BIO-TECHNE CORP
$11.21B$70.87$101.5043.22%Strong Buy421.86%22.81%21.96%16.36%
GMAB
GENMAB A
$24.72B$37.43$45.5021.56%Buy414.45%29.05%N/AN/A
ICPT
INTERCEPT PHARMACEUTICALS INC
$452.09M$10.82$23.00112.57%Buy835.12%6.32%N/AN/A
CPRX
CATALYST PHARMACEUTICALS INC
$1.30B$12.18$25.00105.25%Strong Buy3-3.72%-3.96%N/AN/A
PGEN
PRECIGEN INC
$357.68M$1.40$10.00614.29%Buy232.54%N/AN/AN/A
LGND
LIGAND PHARMACEUTICALS INC
$1.06B$61.06$116.3390.52%Strong Buy324.35%8.92%N/AN/A
INCY
INCYTE CORP
$13.53B$60.37$82.5536.73%Buy1113.61%68.58%N/AN/A
TBPH
THERAVANCE BIOPHARMA INC
$478.49M$9.06$20.00120.75%Buy128.42%N/AN/AN/A
HALO
HALOZYME THERAPEUTICS INC
$5.22B$39.60$56.0041.41%Strong Buy616.01%46.34%N/AN/A
CMRX
CHIMERIX INC
$93.46M$1.06$8.00658.29%Buy3-18.73%N/AN/AN/A
LIFE
ATYR PHARMA INC
$92.41M$1.62$24.671,422.65%Strong Buy358.60%N/AN/AN/A
EXEL
EXELIXIS INC
$6.85B$21.51$25.6319.13%Strong Buy813.35%58.22%N/AN/A
VNDA
VANDA PHARMACEUTICALS INC
$246.14M$4.28N/AN/AN/AN/A5.16%5.46%N/AN/A
MRNA
MODERNA INC
$39.40B$103.53$142.3337.48%Buy9-0.04%20.78%N/AN/A
ZYME
ZYMEWORKS INC
$450.37M$6.64$13.2098.80%Buy5-34.31%N/AN/AN/A
LPCN
LIPOCINE INC
$17.12M$3.22$33.00924.84%Strong Buy11,792.74%N/A28.49%26.68%
APRE
APREA THERAPEUTICS INC
$16.25M$4.35$20.00359.77%Buy1786.80%N/AN/AN/A
CLGN
COLLPLANT BIOTECHNOLOGIES LTD
$69.57M$6.10$11.0080.33%Buy1142.67%N/AN/AN/A
PRTA
PROTHENA CORP PUBLIC LTD CO
$2.81B$52.50$88.4068.38%Buy558.57%N/AN/AN/A
CLNN
CLENE INC
$61.89M$0.48$7.201,393.78%Strong Buy5810.63%N/AN/AN/A
GTHX
G1 THERAPEUTICS INC
$69.34M$1.34$11.40750.75%Buy536.53%N/AN/AN/A
ENTX
ENTERA BIO LTD
$19.74M$0.69$10.001,359.85%Buy1601.97%N/AN/AN/A
GNFT
GENFIT SA
$185.39M$3.72$11.00195.70%Buy137.80%N/AN/AN/A
AGIO
AGIOS PHARMACEUTICALS INC
$1.37B$24.56$37.0050.65%Buy2119.91%N/AN/AN/A
NRBO
NEUROBO PHARMACEUTICALS INC
$20.33M$0.53N/AN/AN/AN/AN/AN/AN/AN/A
VRCA
VERRICA PHARMACEUTICALS INC
$168.26M$4.00$11.50187.50%Strong Buy4136.89%N/AN/AN/A
CRSP
CRISPR THERAPEUTICS AG
$3.70B$46.56$71.0052.49%Buy14109.39%N/AN/AN/A
SELB
SELECTA BIOSCIENCES INC
$164.17M$1.07$3.25203.74%Buy420.14%N/AN/AN/A
CRDF
CARDIFF ONCOLOGY INC
$72.82M$1.63$12.00636.20%Buy1269.34%N/AN/AN/A
STOK
STOKE THERAPEUTICS INC
$196.50M$4.44$22.17399.26%Buy676.80%N/AN/AN/A
BCYC
BICYCLE THERAPEUTICS PLC
$894.27M$21.59$49.00126.96%Strong Buy840.29%N/AN/AN/A
AUPH
AURINIA PHARMACEUTICALS INC
$1.20B$8.34$15.0079.86%Strong Buy247.67%N/AN/AN/A
AUTL
AUTOLUS THERAPEUTICS PLC
$481.10M$2.77$7.50170.76%Strong Buy4174.11%N/AN/AN/A
CARM
CARISMA THERAPEUTICS INC
$178.06M$4.42$11.00148.87%Buy336.40%N/AN/AN/A
VBLT
VASCULAR BIOGENICS LTD
$17.16M$0.22N/AN/AN/AN/A8.19%N/AN/AN/A
ORTX
ORCHARD THERAPEUTICS PLC
$160.42M$7.06$24.50247.03%Strong Buy254.73%N/A-562.62%-264.11%
ZLAB
ZAI LAB LTD
$2.50B$25.39$87.50244.62%Strong Buy381.16%N/AN/AN/A
ALLO
ALLOGENE THERAPEUTICS INC
$631.95M$3.77$18.06378.94%Buy9818.01%N/AN/AN/A
XENE
XENON PHARMACEUTICALS INC
$2.30B$35.84$51.6744.16%Strong Buy6748.34%N/AN/AN/A
SPRO
SPERO THERAPEUTICS INC
$64.82M$1.23$7.00469.11%Buy1N/AN/AN/AN/A
AXSM
AXSOME THERAPEUTICS INC
$3.48B$73.70$108.4347.12%Strong Buy750.90%N/AN/AN/A
EDIT
EDITAS MEDICINE INC
$648.98M$7.95$14.0076.10%Buy683.65%N/AN/AN/A
SLGL
SOL-GEL TECHNOLOGIES LTD
$58.67M$2.11$9.50350.24%Strong Buy2120.97%N/AN/AN/A
DNLI
DENALI THERAPEUTICS INC
$3.05B$22.22$65.00192.53%Strong Buy6-3.45%N/AN/AN/A
ONTX
ONCONOVA THERAPEUTICS INC
$15.98M$0.76$11.001,343.57%Buy132.74%N/A-120.99%-75.05%
VRNA
VERONA PHARMA PLC
$1.35B$16.94$32.2590.38%Strong Buy4646.96%N/AN/AN/A
CARA
CARA THERAPEUTICS INC
$96.80M$1.79$16.50821.79%Buy6121.89%N/AN/AN/A
LUMO
LUMOS PHARMA INC
$23.01M$2.90$18.33532.17%Strong Buy3143.98%N/AN/AN/A
DOMH
DOMINARI HOLDINGS INC
$13.68M$2.56N/AN/AN/AN/A28,069.01%N/A-19.12%-17.45%
BNTX
BIONTECH SE
$26.04B$108.61$150.7338.78%Buy11-32.29%-60.03%N/AN/A
MDWD
MEDIWOUND LTD
$65.63M$9.05$29.50225.97%Buy232.16%N/AN/AN/A
CGEN
COMPUGEN LTD
$90.00M$1.02$8.00684.31%Strong Buy3104.25%N/AN/AN/A
VRDN
VIRIDIAN THERAPEUTICS INC
$714.88M$16.37$42.56159.96%Strong Buy9358.06%N/AN/AN/A
PLUR
PLURI INC
$24.81M$0.60N/AN/AN/AN/A251.99%N/A1,531.15%402.55%
PLX
PROTALIX BIOTHERAPEUTICS INC
$122.40M$1.71N/AN/AN/AN/AN/AN/AN/AN/A
CORT
CORCEPT THERAPEUTICS INC
$3.29B$32.04$30.40-5.12%Buy510.80%26.58%N/AN/A
MGNX
MACROGENICS INC
$281.25M$4.54$12.00164.32%Strong Buy329.44%N/AN/AN/A
DTIL
PRECISION BIOSCIENCES INC
$49.48M$0.43$2.50481.40%Strong Buy265.68%N/AN/AN/A
MRKR
MARKER THERAPEUTICS INC
$47.13M$5.35N/AN/AN/AN/A73.14%N/AN/AN/A
QURE
UNIQURE NV
$356.35M$7.47$41.00448.86%Strong Buy622.12%N/AN/AN/A
RNA
AVIDITY BIOSCIENCES INC
$523.12M$7.06$31.60347.59%Strong Buy5184.46%N/AN/AN/A
FULC
FULCRUM THERAPEUTICS INC
$273.87M$4.43$11.00148.31%Buy494.44%N/AN/AN/A
MRSN
MERSANA THERAPEUTICS INC
$153.04M$1.27$4.60262.20%Hold556.92%N/AN/AN/A
SAGE
SAGE THERAPEUTICS INC
$1.19B$19.90$29.8750.09%Hold15259.74%N/AN/AN/A
REGN
REGENERON PHARMACEUTICALS INC
$90.28B$831.62$907.899.17%Strong Buy181.80%1.39%N/AN/A
BLUE
BLUEBIRD BIO INC
$336.90M$3.15$6.70112.76%Buy6165.53%N/AN/AN/A
PULM
PULMATRIX INC
$7.93M$2.17$10.00360.83%Buy124.89%N/AN/AN/A
MESO
MESOBLAST LTD
$213.32M$1.31$6.83421.60%Hold3436.04%N/A1,110.56%832.55%
DBVT
DBV TECHNOLOGIES SA
$282.02M$1.47$7.00377.82%Buy2201.62%N/AN/AN/A
SEER
SEER INC
$150.26M$2.35N/AN/AN/AN/A90.24%N/AN/AN/A
JANX
JANUX THERAPEUTICS INC
$451.24M$9.78$29.50201.64%Buy2342.04%N/A-48.38%-42.42%
NRIX
NURIX THERAPEUTICS INC
$444.89M$9.23$26.60188.19%Buy536.14%N/AN/AN/A
IMGN
IMMUNOGEN INC
$3.64B$14.64$23.0057.16%Strong Buy738.87%N/AN/AN/A
AMLX
AMYLYX PHARMACEUTICALS INC
$1.25B$18.57$49.67167.53%Strong Buy360.34%N/AN/AN/A
CALT
CALLIDITAS THERAPEUTICS AB
$487.96M$16.38$34.00107.57%Buy281.44%N/AN/AN/A
TFFP
TFF PHARMACEUTICALS INC
$12.18M$0.34$5.501,536.90%Strong Buy2471.77%N/AN/AN/A
LQDA
LIQUIDIA CORP
$406.57M$6.28$12.3396.39%Hold397.99%N/AN/AN/A
IMNN
IMUNON INC
$10.21M$1.09$12.001,000.92%Buy1283.06%N/AN/AN/A
IGMS
IGM BIOSCIENCES INC
$406.81M$6.97$20.67196.51%Buy6292.50%N/AN/AN/A
ACST
ACASTI PHARMA INC
$14.30M$1.92N/AN/AN/AN/AN/AN/A13.26%11.63%
SGMO
SANGAMO THERAPEUTICS INC
$149.13M$0.84$6.07621.02%Buy711.29%N/AN/AN/A
ENTA
ENANTA PHARMACEUTICALS INC
$265.72M$12.62$31.60150.40%Hold593.62%N/AN/AN/A
CLLS
CELLECTIS SA
$90.60M$1.63$11.00574.85%Strong Buy3108.25%N/AN/AN/A
INO
INOVIO PHARMACEUTICALS INC
$104.55M$0.39$2.00412.82%Hold186.57%N/AN/AN/A
CRNX
CRINETICS PHARMACEUTICALS INC
$1.57B$28.62$45.1457.73%Strong Buy7116.77%N/AN/AN/A
AADI
AADI BIOSCIENCE INC
$128.48M$5.24$45.00758.78%Buy112.83%N/AN/AN/A
NTLA
INTELLIA THERAPEUTICS INC
$3.01B$33.99$75.77122.92%Strong Buy1344.00%N/AN/AN/A
MIRM
MIRUM PHARMACEUTICALS INC
$1.19B$31.08$72.33132.73%Strong Buy358.24%N/AN/AN/A
MIST
MILESTONE PHARMACEUTICALS INC
$97.81M$2.93$14.00377.82%Buy3201.85%N/AN/AN/A
ARVN
ARVINAS INC
$1.30B$24.23$62.30157.12%Strong Buy1025.17%N/AN/AN/A
LXRX
LEXICON PHARMACEUTICALS INC
$284.11M$1.16$8.00589.66%Strong Buy1701.33%N/AN/AN/A
VIR
VIR BIOTECHNOLOGY INC
$1.26B$9.37$35.83282.42%Buy64.38%N/AN/AN/A
CUE
CUE BIOPHARMA INC
$104.76M$2.33$11.00372.10%Strong Buy3136.40%N/AN/AN/A

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Sep 2023?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Arcturus Therapeutics Holdings (NASDAQ:ARCT)


Arcturus Therapeutics Holdings (NASDAQ:ARCT) is the top biotech stock with a Zen Score of 75, which is 50 points higher than the biotech industry average of 25. It passed 24 out of 33 due diligence checks and has strong fundamentals. Arcturus Therapeutics Holdings has seen its stock return 76.73% over the past year, overperforming other biotech stocks by 110 percentage points.

Arcturus Therapeutics Holdings has an average 1 year price target of $53.00, an upside of 99.92% from Arcturus Therapeutics Holdings's current stock price of $26.51.

Arcturus Therapeutics Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Arcturus Therapeutics Holdings, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 66, which is 41 points higher than the biotech industry average of 25. It passed 22 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -14% over the past year, overperforming other biotech stocks by 19 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $59.43, an upside of 59.11% from Harmony Biosciences Holdings's current stock price of $37.35.

Harmony Biosciences Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Harmony Biosciences Holdings, 42.86% have issued a Strong Buy rating, 42.86% have issued a Buy, 14.29% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the third best biotech stock with a Zen Score of 64, which is 39 points higher than the biotech industry average of 25. It passed 20 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock return 27.61% over the past year, overperforming other biotech stocks by 60 percentage points.

Voyager Therapeutics has an average 1 year price target of $16.00, an upside of 107.93% from Voyager Therapeutics's current stock price of $7.70.

Voyager Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Voyager Therapeutics, 66.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Kineta (NASDAQ:KA)


Kineta (NASDAQ:KA) has an annual dividend yield of 452.94%, which is 376 percentage points higher than the biotech industry average of 77.42%.

Kineta's dividend payout ratio of -565.5% indicates that its high dividend yield might not be sustainable for the long-term.

2. Carisma Therapeutics (NASDAQ:CARM)


Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of 8.18%, which is -69 percentage points lower than the biotech industry average of 77.42%.

Carisma Therapeutics's dividend payout ratio of -29.6% indicates that its high dividend yield might not be sustainable for the long-term.

3. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.42%, which is -76 percentage points lower than the biotech industry average of 77.42%.

Royalty Pharma's dividend payout ratio of 141.8% indicates that its dividend yield might not be sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -1.75% in the last day, and down -3.58% over the last week. Seelos Therapeutics was the among the top losers in the biotechnology industry, dropping -69.5% yesterday.

Seelos Therapeutics shares are trading lower after the company announced a $4.5 million registered direct offering of 15 million shares at $0.30 per share.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Arcturus Therapeutics Holdings (NASDAQ:ARCT)


Arcturus Therapeutics Holdings (NASDAQ:ARCT) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Arcturus Therapeutics Holdings has a valuation score of 100, which is 75 points higher than the biotech industry average of 25. It passed 7 out of 7 valuation due diligence checks.

Arcturus Therapeutics Holdings's stock has gained 76.73% in the past year. It has overperformed other stocks in the biotech industry by 110 percentage points.

2. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 75 points higher than the biotech industry average of 25. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has gained 27.61% in the past year. It has overperformed other stocks in the biotech industry by 60 percentage points.

3. Orgenesis (NASDAQ:ORGS)


Orgenesis (NASDAQ:ORGS) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Orgenesis has a valuation score of 100, which is 75 points higher than the biotech industry average of 25. It passed 7 out of 7 valuation due diligence checks.

Orgenesis's stock has dropped -63.58% in the past year. It has underperformed other stocks in the biotech industry by -31 percentage points.

Are biotech stocks a good buy now?

52.99% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 97.57% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 13.86x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.